Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis Subcutaneous Abatacept Ultrasound
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 25
Healthy volunteers: no

Brief summary:
Rheumatoid arthritis (RA) is a chronic inflammatory disease (a long-lasting disease causing pain and swelling) associated with significant health problems. It is a difficult disease to manage as the disease is often unpredictable. RA causes inflammation (swelling) of the joints that can cause joint damage, deformity, and progressive disability and impairment. It is estimated that 1% of the world's population suffers from this disease.

The purpose of this research study is to determine if a change in inflammation seen on the ultrasound is a good indicator of how subjects' rheumatoid arthritis is responding to treatment of subcutaneous abatacept at 3 weeks, 3 months, 6 months, and 12 months.

Detailed description:

Arms:
arm 1: All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.

Interventions: intervention 1: abatacept
Intervention descriptions: intervention 1: 125 mg once a week up to 12 months.

Protocol document: